Update of research on the role of EZH2 in cancer progression

References

• CaoRWangLWangHRole of histone H3 lysine 27 methylation in polycomb-group silencingScience200229855951039104312351676
   PubMed Web of Science ®Google Scholar
• KunjuLPCookinghamCToyKAChenWSabelMSKleerCGEZH2 and ALDH-1 mark breast epithelium at risk for breast cancer developmentMod Pathol201124678679321399615
   PubMed Web of Science ®Google Scholar
• MargueronRReinbergDThe polycomb complex PRC2 and its mark in lifeNature2011469733034334921248841
   PubMed Web of Science ®Google Scholar
• MinJZaslavskyAFedeleGAn oncogene-tumor suppressor cascade drives metastatic prostate cancer by coordinately activating Ras and nuclear factor-κBNat Med201016328629420154697
   PubMed Web of Science ®Google Scholar
• CreaFMathewsLAFarrarWLHurtEMTargeting prostate cancer stem cellsAnticancer Agents Med Chem20099101105111319925394
   PubMed Web of Science ®Google Scholar
• ChangCJHungMCThe role of EZH2 in tumour progressionBr J Cancer2012106224324722187039
   PubMed Web of Science ®Google Scholar
• ChaTLZhouBPXiaWAkt-mediated phosphorylation of EZH2 suppresses methylation of lysine 27 in histone H3Science2005310574630631016224021
   PubMed Web of Science ®Google Scholar
• ChenBLiuJChangQBeezholdKLuYChenFJNK and STAT3 signaling pathways converge on Akt-mediated phosphorylation of EZH2 in bronchial epithelial cells induced by arsenicCell Cycle201312111212123255093
   PubMed Web of Science ®Google Scholar
• SuvaMLRiggiNJaniszewskaMEZH2 is essential for glioblastoma cancer stem cell maintenanceCancer Res200969249211921819934320
   PubMed Web of Science ®Google Scholar
• van LeendersGJDukersDHesselsDPolycomb-group oncogenes EZH2, BMI1, and RING1 are overexpressed in prostate cancer with adverse pathologic and clinical featuresEur Urol200752245546317134822
   PubMed Web of Science ®Google Scholar
• BryantRJCrossNAEatonCLHamdyFCCunliffeVTEZH2 promotes proliferation and invasiveness of prostate cancer cellsProstate200767554755617252556
   PubMed Web of Science ®Google Scholar
• RenGBaritakiSMaratheHPolycomb protein EZH2 regulates tumor invasion via the transcriptional repression of the metastasis suppressor RKIP in breast and prostate cancerCancer Res201272123091310422505648
   PubMed Web of Science ®Google Scholar
• ShinYJKimJHThe role of EZH2 in the regulation of the activity of matrix metalloproteinases in prostate cancer cellsPLoS One201271e3039322272343
   PubMed Web of Science ®Google Scholar
• BachmannNHoegelJHaeuslerJMutation screen and association study of EZH2 as a susceptibility gene for aggressive prostate cancerProstate200565325225916015586
   PubMed Web of Science ®Google Scholar
• XuKWuZJGronerACEZH2 oncogenic activity in castration-resistant prostate cancer cells is polycomb-independentScience201233861131465146923239736
   PubMed Web of Science ®Google Scholar
• KleerCGCaoQVaramballySEZH2 is a marker of aggressive breast cancer and promotes neoplastic transformation of breast epithelial cellsProc Natl Acad Sci USA200310020116061161114500907
   PubMed Web of Science ®Google Scholar
• ReijmEAJansenMPRuigrok-RitstierKDecreased expression of EZH2 is associated with upregulation of ER and favorable outcome to tamoxifen in advanced breast cancerBreast Cancer Res Treat2011125238739420306127
   PubMed Web of Science ®Google Scholar
• StefanssonOAEstellerMEZH2-mediated epigenetic repression of DNA repair in promoting breast tumor initiating cellsBreast Cancer Res201113330921672285
   PubMed Web of Science ®Google Scholar
• HolmKGrabauDLovgrenKGlobal H3K27 trimethylation and EZH2 abundance in breast tumor subtypesMol Oncol20126549450622766277
   PubMed Web of Science ®Google Scholar
• GonzalezMELiXToyKDownregulation of EZH2 decreases growth of estrogen receptor-negative invasive breast carcinoma and requires BRCA1Oncogene200928684385319079346
   PubMed Web of Science ®Google Scholar
• PuppeJDrostRLiuXBRCA1-deficient mammary tumor cells are dependent on EZH2 expression and sensitive to polycomb repressive complex 2-inhibitor 3-deazaneplanocin ABreast Cancer Res2009114R6319709408
   PubMed Web of Science ®Google Scholar
• ShiBLiangJYangXIntegration of estrogen and Wnt signaling circuits by the polycomb group protein EZH2 in breast cancer cellsMol Cell Biol200727145105511917502350
   PubMed Web of Science ®Google Scholar
• LeeSTLiZWuZContext-specific regulation of NF-κB target gene expression by EZH2 in breast cancersMol Cell201143579881021884980
   PubMed Web of Science ®Google Scholar
• RaoZYCaiMYYangGFEZH2 supports ovarian carcinoma cell invasion and/or metastasis via regulation of TGF-β1 and is a predictor of outcome in ovarian carcinoma patientsCarcinogenesis20103191576158320668008
   PubMed Web of Science ®Google Scholar
• RizzoSHerseyJMMellorPOvarian cancer stem cell-like side populations are enriched following chemotherapy and overexpress EZH2Mol Cancer Ther201110232533521216927
   PubMed Web of Science ®Google Scholar
• LiHBitlerBGVathipadiekalVALDH1A1 is a novel EZH2 target gene in epithelial ovarian cancer identified by genome-wide approachesCancer Prev Res (Phila)20125348449122144423
   PubMed Web of Science ®Google Scholar
• LuCHanHDMangalaLSRegulation of tumor angiogenesis by EZH2Cancer Cell201018218519720708159
   PubMed Web of Science ®Google Scholar
• KikuchiJKinoshitaIShimizuYDistinctive expression of the polycomb group proteins Bmi1 polycomb ring finger oncogene and enhancer of zeste homolog 2 in nonsmall cell lung cancers and their clinical and clinicopathologic significanceCancer2010116123015302420564407
   PubMed Web of Science ®Google Scholar
• HuqunIshikawaRZhangJEnhancer of zeste homolog 2 is a novel prognostic biomarker in nonsmall cell lung cancerCancer201211861599160621837672
   PubMed Web of Science ®Google Scholar
• ZhangHZhangHZhaoMMiR-138 inhibits tumor growth through repression of EZH2 in non-small cell lung cancerCell Physiol Biochem2013311566523343715
   PubMedGoogle Scholar
• PiuntiAPasiniDEpigenetic factors in cancer development: polycomb group proteinsFuture Oncol201171577521174538
   PubMed Web of Science ®Google Scholar
• FiskusWWangYSreekumarACombined epigenetic therapy with the histone methyltransferase EZH2 inhibitor 3-deazaneplanocin A and the histone deacetylase inhibitor panobinostat against human AML cellsBlood2009114132733274319638619
   PubMed Web of Science ®Google Scholar
• AvanACreaFPaolicchiEMolecular mechanisms involved in the synergistic interaction of the EZH2 inhibitor 3-deazaneplanocin A with gemcitabine in pancreatic cancer cellsMol Cancer Ther20121181735174622622284
   PubMed Web of Science ®Google Scholar
• McCabeMTOttHMGanjiGEZH2 inhibition as a therapeutic strategy for lymphoma with EZH2-activating mutationsNature2012492742710811223051747
   PubMed Web of Science ®Google Scholar